CVS Health (NYSE:CVS) Shares Gap Down – Time to Sell?

CVS Health Corporation (NYSE:CVS)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $104.42, but opened at $93.72. CVS Health shares last traded at $98.14, with a volume of 4,669,111 shares trading hands.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Quarterly results exceeded expectations. CVS reported adjusted EPS of $2.58, well above the $1.86–$1.87 consensus, while revenue rose 7.3% year over year to $106.1 billion, surpassing estimates near $100 billion. All three segments—Aetna insurance, pharmacy and health services—outperformed revenue expectations. CVS blows past estimates, hikes guidance as insurance unit continues to improve
• Positive Sentiment: Profitability and cash flow improved. A more profitable pharmacy drug mix, lower medical costs and bonus payments tied to highly rated government health plans helped drive a nearly threefold increase in quarterly profit. CVS generated $10.6 billion in year-to-date operating cash flow. CVS raises annual profit forecast on improved drug revenues
• Positive Sentiment: Management raised 2026 guidance. Adjusted EPS is now expected at $7.90–$8.10, up from $7.30–$7.50 and above the approximately $7.44 analyst consensus. CVS also raised its GAAP EPS and operating cash-flow targets. CVS Health Corporation reports strong second quarter 2026 results and raises full-year 2026 guidance
• Positive Sentiment: CVS expanded its weight-management strategy. A new collaboration with Eli Lilly will support access to Zepbound and other GLP-1 medications, while CVS lowered MinuteClinic digital weight-loss visits to $29. The initiative could strengthen customer engagement and create growth opportunities in a rapidly expanding category. CVS Health enhances direct-to-consumer weight management offerings
• Negative Sentiment: Investors focused on cautious guidance and sustainability. Despite the sizable earnings beat and improved Aetna performance, the outlook was viewed as cautious, raising concerns about whether recent medical-cost improvements and pharmacy benefits will persist. That reaction outweighed the headline results and guidance increase in trading.

Analysts Set New Price Targets

CVS has been the subject of several analyst reports. Robert W. Baird boosted their price target on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Cantor Fitzgerald raised their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Wall Street Zen upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, July 23rd. Wells Fargo & Company raised their price target on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Finally, Weiss Ratings raised CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, July 20th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $105.67.

CVS Health Trading Down 6.0%

The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $125.26 billion, a PE ratio of 43.25, a PEG ratio of 1.03 and a beta of 0.61. The business’s 50-day moving average is $101.96 and its two-hundred day moving average is $87.43.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.72. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the company posted $1.81 earnings per share. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, analysts anticipate that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.7%. CVS Health’s payout ratio is 117.18%.

Insiders Place Their Bets

In other news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. The trade was a 24.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 over the last ninety days. Corporate insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On CVS Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp raised its position in CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after buying an additional 1,245,457 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of CVS Health by 0.3% in the fourth quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock valued at $738,777,000 after acquiring an additional 31,249 shares in the last quarter. Deutsche Bank AG increased its stake in shares of CVS Health by 28.4% during the fourth quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock worth $370,333,000 after acquiring an additional 1,031,998 shares during the period. KBC Group NV raised its holdings in CVS Health by 200.4% during the fourth quarter. KBC Group NV now owns 676,809 shares of the pharmacy operator’s stock worth $53,711,000 after purchasing an additional 451,521 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. purchased a new position in CVS Health during the fourth quarter worth about $3,333,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.